Summary & Overview
HCPCS Q4197: Puraply xt per square centimeter (add-on)
HCPCS Level II code Q4197 identifies Puraply xt, billed per square centimeter as an add-on item used in advanced wound care and biologic dressing applications. As an add-on code, Q4197 is reported in addition to a primary procedure when the product is applied to a wound bed and is billed per unit area. Nationally, such product-specific add-on codes matter because they standardize reporting for biologic and synthetic graft materials, support clinical documentation, and influence facility and payer processing for complex wound care services.
Key payers addressed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise review of the clinical context for use, typical sites of service, and the role of add-on HCPCS codes in billing workflows. The publication also summarizes common modifiers and administrative considerations when reporting add-on biologic products, outlines where to look for payer-specific coverage policies, and highlights the types of benchmarks and policy updates readers can expect to see in the full analysis. Data not available in the input for taxonomies, ICD-10 pairings, and payer-specific pricing and utilization is noted where applicable.
Billing Code Overview
HCPCS Level II code Q4197 describes Puraply xt, billed per square centimeter. This is an add-on, list separately item intended to be reported in conjunction with a primary procedure that employs an advanced wound care or biologic dressing product. The service type is advanced wound care / biologic graft application, and the typical site of service is outpatient settings where wound management procedures are performed, such as ambulatory surgery centers, hospital outpatient departments, and outpatient wound care clinics.
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A patient presents to an outpatient wound care clinic with a chronic non-healing full-thickness wound following soft-tissue loss after debridement of an ulcer or traumatic wound. The clinician (often a wound care specialist, plastic surgeon, or podiatrist) performs sharp surgical debridement of necrotic tissue followed by application of an advanced biologic dressing, in this case Q4197 (Puraply XT) billed per square centimeter as an add-on to the primary procedure. The typical workflow includes wound assessment and measurement, photographic documentation, obtaining informed consent, surgical preparation and local or regional anesthesia, thorough debridement or preparation of the wound bed, sizing and trimming of the Puraply XT graft to fit the defect, securing the product with sutures, staples, or a secondary dressing, and post-application wound care instructions with scheduled follow-up for dressing changes and evaluation of graft take. Typical settings for this service are outpatient wound care clinics, ambulatory surgery centers, hospital outpatient departments, or office-based procedure suites where minor surgical procedures are performed under local anesthesia. The typical patient scenario includes comorbidities such as diabetes mellitus, peripheral vascular disease, or prior radiation to the area that contribute to impaired healing and the need for biological grafting materials. Documentation should include wound dimensions (cm²), clinical indication for grafting, primary procedure code supporting placement of the biologic material, exact quantity (square centimeters) of Q4197 applied, and any applicable modifier(s) to reflect unusual circumstances (for example, significant additional work or separate surgeon).
Coding Specifications
| Modifier | Description | When to Use |
|---|